References
- Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010;15:994–1001.
- Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709–20.
- Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 2009;4:49–70.
- Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35.
- Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781–9.
- Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121:2465–72.
- Lewis JS Jr, Thorstad WL, Chernock RD, Haughey BH, Yip JH. Zhang Q, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010;34:1088–96.
- Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128–37.
- Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK, Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007;120:1731–8.
- Lundberg M, Pajusto M, Koskinen WJ, Makitie AA, Aaltonen LM, Mattila PS. Association between transforming growth factor beta1 genetic polymorphism and response to chemoradiotherapy in head and neck squamous cell cancer. Head Neck 2009;31:664–72.
- Lundberg M, Saarilahti K, Makitie AA, Mattila PS. TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis. Oral Oncol 2010;46:369–72.
- Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610–15.
- Guan X, Sturgis EM, Lei D, Liu Z, Dahlstrom KR, Wei Q, Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer. Clin Cancer Res 2010;16:1416–22.
- Peralta-Zaragoza O, Bermudez-Morales V, Gutierrez-Xicotencatl L, Alcocer-Gonzalez J, Recillas-Targa F, Madrid-Marina V. E6 and E7 oncoproteins from human papillomavirus type 16 induce activation of human transforming growth factor beta1 promoter throughout Sp1 recognition sequence. Viral Immunol 2006;19:468–80.
- Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259–73.
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–15.
- Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 2008;26:2871–5.
- Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26:2839–45.
- Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, Blockade of TGF-β signaling by the TGFßR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011;71:7155–67.
- Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri RJ, TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol 2008;70:752–9.